CHROMIC SULFATE PENTADECAHYDRATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	2Cr.3O4S.15H2O
Molecular Weight	662.409
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of CHROMIC SULFATE PENTADECAHYDRATE

Structure Search

SMILES

O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O

InChI

InChIKey=BWSOELSKLHYQRA-UHFFFAOYSA-H

InChI=1S/2Cr.3H2O4S.15H2O/c;;3*1-5(2,3)4;;;;;;;;;;;;;;;/h;;3*(H2,1,2,3,4);15*1H2/q2*+3;;;;;;;;;;;;;;;;;;/p-6

HIDE SMILES / InChI

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Cr
Molecular Weight	51.9961
Charge	3
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	H2O4S
Molecular Weight	98.078
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10630581 | https://www.ncbi.nlm.nih.gov/pubmed/28954488

Chromium sulfate(III) hexahydrate or chromium sulphate, a trivalent compound of chromium that was investigated as a toxic compound. Experiments on rodent have shown chromium sulfate produced severe and widespread effects in the nasal cavity, larynx, lungs, and mediastinal lymph node. Effects were characterized by the accumulation of foreign material, infiltration of alveolar macrophages, septal cell hyperplasia, and granulomatous and chronic inflammation. Besides, chromium sulphate exerted a disadvantageous effect on the skeleton, as it decreases bone density and resistance.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
transmembrane receptor protein tyrosine kinase activity 22 Target ID: GO:0004714 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15924436	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chromium deficiency 22 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4d01ebb-a36e-44b7-028c-43c0ab2d13b4	Preventing		Approved 8429	CHROMIUM Approved Use Chromium 4 mcg/mL (Chromic Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition. Administration helps to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. Launch Date 2005

PubMed

Title	Date	PubMed
Cytokine induction in human epidermal keratinocytes exposed to contact irritants and its relation to chemical-induced inflammation in mouse skin.	1994 Jun	8006454
The role of oxidative stress in the modulation of aryl hydrocarbon receptor-regulated genes by As3+, Cd2+, and Cr6+.	2005 Dec 1	16274885
Effects of subchronic exposure via drinking water to a mixture of eight water-contaminating metals: a biochemical and histopathological study in male rats.	2007 Nov	17882470

Patents

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:28:33 GMT 2023` Edited by `admin` on `Fri Dec 15 17:28:33 GMT 2023`
Record UNII	E4T8TU3LE8
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CHROMIC SULFATE PENTADECAHYDRATE

Common Name

English

CHROMIUM SULPHATE, PENTADECAHYDRATE

Common Name

English

CHROMIUM SULPHURICUM [HPUS]

Common Name

English

CHROMIUM SULFATE, PENTADECAHYDRATE

Common Name

English

SULFURIC ACID, CHROMIUM(3+) SALT (3:2), PENTADECAHYDRATE

Common Name

English

CHROMIC SULPHATE PENTADECAHYDRATE

Common Name

English

WOOL MORDANT

Common Name

English

CHROMIUM SULPHURICUM

Common Name

English

Code System Code Type Description

FDA UNII

E4T8TU3LE8